Pityriasis rubra pilaris mixed type III/IV successfully treated with narrow band-ultraviolet B

Massa, António Fernandes; Vasconcelos, Pedro; Soares‐de‐Almeida, Luís; Filipe, Paulo

doi:10.4103/0378-6323.156196

Cited by 9 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another option is methotrexate treatment, though it appears to be less effective compared to retinoid therapy [46,52]. A variety of responses to PRP phototherapy have been reported in the literature, including exacerbation, lack of efficacy, and reduction in symptoms severity [53][54][55]. Other reported therapies with lower efficacy include azathioprine, cyclosporin A, apremilast, mycophenolate mofetil, penicillin, dimethyl fumarate, extracorporeal photophoresis, and intravenous immunoglobulins [1,46].…”

Section: Discussionmentioning

confidence: 99%

Pityriasis rubra pilaris secondary to viral infection

Pawlik,

Jarosz-Chudek,

Dyduch

et al. 2023

View full text Add to dashboard Cite

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) Dermatology Review/Przegląd Dermatologiczny 2023/5 620 of Dermatology (OKD) of the University Hospital in Krakow, who developed symptoms of PRP after a viral infection, and provide insights into the nature of the disease. Case reportA 67-year-old male patient, a retired entrepreneur, was admitted to the OKD for the diagnosis and treatment of rapidly progressive erythematous papular skin rash. The first skin lesions, presenting as erythema on the face and palms, appeared approximately 2 weeks prior to hospitalisation. Subsequently, ery-abstraCt Introduction: Pityriasis rubra pilaris is a rare, chronic dermatosis presenting with erythema and papular eruptions as well as characteristic perifollicular hyperkeratosis and 'islands of sparing' (normal appearing skin). In the literature, there are reports of cases where symptoms of infection preceded the onset of pityriasis rubra pilaris. Objective: Presentation of the case of a 67-year-old patient with type I pityriasis rubra pilaris to highlight the possible association between pityriasis rubra pilaris with infectious agents. Case report: A 67-year-old patient was referred to hospital because of rapidly progressive erythematous papular skin rash preceded by symptoms of an upper respiratory tract infection. On physical examination, attention was drawn to perifollicular papules covered with cap-like scales as well as confluent erythema and features of hyperkeratosis on the hands and feet. Based on the clinical presentation and histopathological findings, type I pityriasis rubra pilaris was diagnosed and treatment with acitretin was initiated. Conclusions: Infectious agents have the potential to be a trigger for pityriasis rubra pilaris. Acitretin continues to demonstrate efficacy in the treatment of pityriasis rubra pilaris.

show abstract

Section: Discussionmentioning

confidence: 99%

Pityriasis rubra pilaris secondary to viral infection

Pawlik,

Jarosz-Chudek,

Dyduch

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The 3 studies describing an unusual distribution of PRP lesions were: cyclical lesions on inguinal and scrotal regions (n = 1), persistent lesions on the antecubital and popliteal areas (n = 1), and widespread eruption after a chronic localized disease suggestive of mixed type III/IV disease (n = 1). [18][19][20] Two case reports outlined typical clinical and dermoscopic findings in PRP patients.…”

Section: Clinical Manifestations and Laboratory Findingsmentioning

confidence: 99%

Updates on Pityriasis Rubra Pilaris: A Scoping Review

Zhou,

Al Muqrin,

Abu-Hilal

2024

J Cutan Med Surg

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is a rare, inflammatory papulosquamous skin disease with unknown exact etiology. Historically, PRP has been challenging to diagnose, especially during the acute phase, and to treat, due to its unclear pathogenesis. To better inform clinical practice, a literature review was conducted employing a broad search strategy to capture PRP-related published studies between January 1, 2012 to October 31, 2022. Two hundred twenty-one studies were identified, which were categorized into 9 themes: (1) potential causes and triggering factors, (2) comorbidities, (3) diagnostic difficulties, (4) genetics, (5) clinical manifestations and laboratory values, (6) treatment, (7) treatment-related adverse events, (8) quality of life, and (9) other. COVID-19 infection, COVID-19 vaccination, and malignancy were the most commonly reported potential triggering factors. Misdiagnosis is very common during the early acute stages. Pathogenesis and genetic studies have further implicated caspase recruitment domain family member 14 (CARD14) mutations in the development of familial PRP (Type V) and have underlined the overlap between psoriasis and PRP. To date, there are currently no specific and validated scoring systems or tools to assess the severity of PRP. While large, randomized trials are still lacking, biologic agents remain the most effective therapy.

show abstract

“…Another case report showed complete resolution after four months of NB-UVB for a case of PRP recalcitrant to oral isotretinoin [ 49 ]. Recently, another case report demonstrated 90% improvement after 19 sessions of NB-UVB in an eight-year-old with a generalized eruption of PRP [ 53 , 54 ].…”

Section: Reviewmentioning

confidence: 99%

An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases

Myers¹,

Kheradmand²,

Miller³

2021

Cureus

View full text Add to dashboard Cite

The objective of this review is to provide an update on narrowband ultraviolet B (NB-UVB) as a treatment for various skin conditions. NB-UVB works by suppressing the cutaneous cell-mediated immune response and has been shown to be an efficacious and clinically tolerable treatment for a range of inflammatory dermatoses. A literature search was conducted by advanced searches of PubMed for NB-UVB treatment of dermatologic skin diseases with a focus on reports from 2010 to 2021, including both office-based and home-based phototherapy (HBPT). Data were prioritized based on studies with a high level of evidence using the Oxford Evidence-Based Medicine guidance. We found that NB-UVB continues to serve as an effective form of therapy for several cutaneous conditions, including vitiligo, psoriasis, atopic dermatitis, mycosis fungoides, and other inflammatory dermatoses. The recent introduction of Janus kinase inhibitors in combination with NB-UVB suggests future promise in the treatment of vitiligo. Despite its rise in popularity, a decline was seen in office-based NB-UVB treatment during the coronavirus disease 2019 pandemic. Options are available to deliver NB-UVB at home with comparable efficacy to office-based treatments. In conclusion, for a select group of patients and conditions, NB-UVB continues to serve as an effective treatment modality with minimal side effects, with HBPT serving as an option to improve patient compliance.

show abstract

Pityriasis rubra pilaris mixed type III/IV successfully treated with narrow band-ultraviolet B

Cited by 9 publications

References 1 publication

Pityriasis rubra pilaris secondary to viral infection

Pityriasis rubra pilaris secondary to viral infection

Updates on Pityriasis Rubra Pilaris: A Scoping Review

An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases

Contact Info

Product

Resources

About